Dengue Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (CYD-TDV, Tak-003, Other), By Application (Hospitals, Government Institutes, Non-Governmental Organizations (NGOs)), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

DENGUE VACCINES MARKET OVERVIEW

The global Dengue Vaccines Market size estimated at USD 0.77 billion in 2026 and is projected to reach USD 3.26 billion by 2035, growing at a CAGR of 17.36% from 2026 to 2035.

The Dengue Vaccines Market is expanding due to the rising burden of dengue infections across tropical and subtropical regions. More than 5.2 million dengue cases were reported globally during 2024, while over 129 countries remained at risk of dengue transmission. Vaccine demand increased by 31% in endemic countries due to recurring outbreaks and hospital admissions. CYD-TDV remained active in more than 20 countries, while Tak-003 expanded regulatory access across Asia and Latin America. Public immunization campaigns covered nearly 18 million individuals in high-risk populations during 2025. Government-supported vaccination initiatives increased by 27%, while pediatric vaccination demand accounted for 61% of total administered dengue vaccine doses globally.

The USA dengue vaccines market is witnessing growing attention due to imported dengue cases and rising mosquito exposure in southern states. During 2024, the United States recorded more than 3,800 travel-associated dengue infections and over 1,900 locally acquired cases in Puerto Rico. Florida accounted for 14% of reported mainland infections, while Texas represented 9%. Vaccine awareness programs increased by 24% among travel clinics and infectious disease centers. Research funding for arbovirus prevention crossed 18 federally supported projects in 2025. Hospital surveillance programs expanded by 21%, while mosquito-control monitoring activities increased by 17% across high-risk coastal regions. Pediatric infectious disease consultations related to dengue rose by 13%.

KEY FINDINGS

LATEST TRENDS

The Dengue Vaccines Market is experiencing significant transformation due to rising infection prevalence and increased vaccine deployment programs. More than 3.9 billion people currently live in dengue-risk regions, with urban populations accounting for 72% of exposed communities. Demand for tetravalent dengue vaccines increased by 37% during 2025 because all four dengue virus serotypes continue circulating in Asia-Pacific and Latin America. Pediatric vaccination campaigns represented 59% of total immunization programs, particularly in countries with school-based healthcare systems.

Clinical development activities intensified during 2024, with over 14 active dengue vaccine studies progressing through late-stage trials. Tak-003 adoption expanded across Southeast Asia, while vaccine procurement agreements increased by 32% in Brazil, Indonesia, and the Philippines. Research institutions reported 43% higher investment in vector-borne disease vaccine innovation. Single-dose vaccine formulations gained attention because existing multi-dose regimens experienced 18% patient dropout rates.

MARKET DYNAMICS

Driver

Rising prevalence of dengue infections globally.

The increasing incidence of dengue fever is the strongest growth driver for the Dengue Vaccines Market. More than 500 million individuals face annual exposure risk in densely populated urban regions. During 2024, Brazil reported over 6 million suspected dengue cases, while Southeast Asia accounted for 38% of worldwide infections. Hospital admissions related to severe dengue increased by 23%, particularly among children under 15 years. Government vaccination campaigns expanded by 31% because mosquito-control programs alone failed to reduce outbreaks effectively.

Restraint

Limited vaccine eligibility and safety concerns.

The Dengue Vaccines Market faces restraints because several vaccines remain restricted to specific age groups and previously infected individuals. CYD-TDV eligibility guidelines reduced the potential recipient pool by nearly 44% in certain countries. Safety monitoring requirements increased vaccine rollout timelines by 22%, while public concerns regarding severe dengue risks in seronegative individuals reduced vaccination participation by 17%. Adverse-event surveillance systems increased operational costs for immunization programs by 14%.

Expansion of immunization programs in emerging economies

Opportunity

Emerging economies present substantial growth opportunities for the Dengue Vaccines Market due to rising healthcare investments and expanding immunization infrastructure. Asia-Pacific countries increased vaccine procurement budgets by 28% during 2025, while Latin American public health agencies expanded school-based vaccination campaigns by 24%.

Urban population growth exceeded 3.1% annually in dengue-prone regions, increasing exposure risks and demand for preventive healthcare solutions. International partnerships supporting tropical disease control increased by 32%, enabling broader vaccine access in underserved communities.

High distribution complexity in tropical regions

Challenge

The Dengue Vaccines Market faces operational challenges due to distribution limitations in tropical and low-resource areas. Cold-chain transportation requirements increased vaccine logistics expenses by 23%, especially in remote island nations and rural communities. More than 34% of healthcare facilities in dengue-endemic regions lack advanced refrigeration systems for vaccine storage.

Seasonal outbreak unpredictability caused inventory shortages in 18% of government immunization programs during 2024. Public awareness regarding dengue vaccination remains limited, with only 41% of high-risk populations familiar with available vaccine options.

•   
•   
  

  Download Free Sample to learn more about this report

    

DENGUE VACCINES MARKET SEGMENTATION

By Type

• CYD-TDV: CYD-TDV remained the dominant vaccine type in the Dengue Vaccines Market, accounting for nearly 57% of global administered doses during 2025. The vaccine maintained strong adoption across Latin America and Southeast Asia, where dengue outbreaks increased by 28%. More than 20 countries integrated CYD-TDV into national immunization programs, while pediatric vaccination campaigns represented 63% of its total administration volume. Public healthcare procurement for CYD-TDV increased by 24% during 2024 because high-risk urban populations expanded rapidly.

• Tak-003: Tak-003 represented approximately 34% of the Dengue Vaccines Market due to expanding approvals and broader efficacy profiles. Clinical studies demonstrated efficacy levels above 73% against symptomatic dengue infections, increasing adoption in Asia-Pacific and Latin America. Government procurement agreements for Tak-003 increased by 29% during 2025, while pediatric immunization initiatives expanded by 22%. The vaccine demonstrated improved protection against hospitalization, reducing severe dengue incidence by nearly 84% in monitored populations.

• Other: Other dengue vaccine candidates accounted for nearly 9% of the Dengue Vaccines Market, supported by ongoing clinical trials and experimental vaccine technologies. More than 14 pipeline vaccines were under active development during 2025, including mRNA-based and live attenuated formulations. Research investments in alternative dengue vaccines increased by 33%, while public-private partnerships expanded by 21%. Several candidates demonstrated neutralizing antibody responses above 70% in phase II studies.

By Application

• Hospitals: Hospitals represented nearly 49% of the Dengue Vaccines Market due to high patient admissions during seasonal outbreaks. More than 61% of severe dengue cases required hospitalization during 2024, increasing institutional vaccine procurement. Urban hospitals in Asia-Pacific expanded dengue vaccination units by 26%, while infectious disease departments increased vaccine stock levels by 18%. Pediatric wards accounted for 44% of vaccine administration activities within hospitals. Hospital-based awareness campaigns improved patient vaccination participation by 21%.

• Government Institutes: Government institutes accounted for approximately 36% of dengue vaccine distribution due to national immunization campaigns and public disease-control initiatives. Public vaccination programs covered more than 18 million individuals globally during 2025. School-based immunization campaigns increased by 27%, while community health outreach programs expanded by 19%. Governments in endemic countries allocated 31% higher public health resources toward mosquito-borne disease prevention activities.

• Non-Governmental Organizations (NGOs): Non-governmental organizations contributed nearly 15% of dengue vaccine outreach activities by supporting healthcare access in low-resource communities. NGO-supported vaccination drives expanded by 23% during 2025, particularly in Southeast Asia and Africa. Community awareness campaigns conducted by NGOs improved dengue prevention knowledge by 28% among rural populations. More than 3,000 local healthcare workers received dengue vaccine administration training through international NGO partnerships. Mobile vaccination camps increased rural immunization participation by 17%.

•   
•   
  Download Free Sample to learn more about this report

    

DENGUE VACCINES MARKET REGIONAL OUTLOOK

• North America

North America accounted for approximately 11% of the Dengue Vaccines Market due to imported dengue cases, regional outbreaks, and expanding preventive healthcare programs. The United States reported more than 3,800 travel-associated dengue infections during 2024, while Puerto Rico recorded over 1,900 locally acquired cases. Florida represented 14% of mainland dengue reports because subtropical climates supported mosquito activity.

Government-funded mosquito surveillance programs expanded by 22%, while travel vaccination consultations increased by 19%. Pediatric infectious disease monitoring programs also expanded across southern states. Canada increased tropical disease research funding by 16%, supporting dengue vaccine awareness among international travelers. Hospital preparedness initiatives in North America increased dengue diagnostic capacity by 21%.

• Europe

Europe represented nearly 8% of the Dengue Vaccines Market because of rising imported infections and increasing vector surveillance activities. More than 4,000 imported dengue cases were recorded across European countries during 2024. Southern Europe experienced a 12% increase in mosquito surveillance operations because warmer temperatures expanded vector habitats.

France and Spain accounted for 39% of regional dengue monitoring activities due to overseas territories and tourism-related exposure risks. Travel clinics across Europe increased dengue vaccine consultations by 23%, while tropical disease awareness programs expanded by 18%. Public healthcare systems improved infectious disease screening capacity by 21% at major airports and border health facilities.

• Asia-Pacific

Asia-Pacific dominated the Dengue Vaccines Market with nearly 52% share because of high dengue prevalence, large tropical populations, and strong government vaccination initiatives. More than 2.8 million dengue infections were reported across Southeast Asia during 2024. Indonesia, the Philippines, Thailand, and India accounted for 61% of regional vaccine demand.

School-based immunization programs expanded by 31%, while public mosquito-control campaigns increased by 24%. Government procurement of dengue vaccines increased significantly across Asia-Pacific due to recurring outbreaks and hospital overcrowding. Pediatric populations represented 66% of vaccinated individuals in regional immunization programs.

• Middle East & Africa

Middle East & Africa accounted for approximately 5% of the Dengue Vaccines Market due to increasing dengue outbreaks and expanding mosquito habitats. Urban population growth in tropical African regions exceeded 4%, increasing exposure to mosquito-borne diseases. More than 17 African countries reported dengue outbreaks during 2024, while East African coastal regions experienced a 14% increase in reported infections.

Public health organizations expanded dengue awareness campaigns by 22%, improving vaccination participation in high-risk areas. Government mosquito-control initiatives increased by 19%, while mobile healthcare outreach programs expanded vaccine access in underserved communities. International health partnerships supported more than 2 million dengue prevention interventions during 2025.

LIST OF TOP DENGUE VACCINES COMPANIES

• Sanofi
• Takeda Pharmaceutical

Top Two Companies With Highest Market Share

• Sanofi held approximately 57% market share in the Dengue Vaccines Market due to widespread CYD-TDV adoption across more than 20 countries and strong participation in public immunization campaigns.
• Takeda Pharmaceutical accounted for nearly 34% market share supported by Tak-003 expansion, increasing regulatory approvals, and strong efficacy performance against hospitalization and symptomatic dengue infections.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Dengue Vaccines Market increased significantly during 2025 because global dengue cases continued rising across tropical regions. Public health agencies expanded vaccine procurement investments by 28%, while biotechnology partnerships related to arbovirus vaccine development increased by 24%. More than 14 active dengue vaccine clinical studies received institutional funding support during 2024. Government-backed infectious disease prevention initiatives increased by 31%, particularly in Asia-Pacific and Latin America.

Pharmaceutical manufacturers expanded production facilities by 22% to improve vaccine availability during outbreak periods. Regional manufacturing partnerships reduced supply dependency by 18% in developing countries. Research institutions also increased funding for mRNA-based dengue vaccine technology by 26%. Single-dose vaccine development programs attracted 19% higher private investment because simplified immunization schedules improve compliance rates.

NEW PRODUCT DEVELOPMENT

New product development in the Dengue Vaccines Market is focused on improving efficacy, reducing dosing complexity, and enhancing protection against all four dengue serotypes. More than 14 vaccine candidates remained under active development during 2025, including live attenuated, recombinant, and mRNA-based technologies. Single-dose vaccine research programs increased by 33% because current multi-dose schedules experience compliance gaps above 20%.

Biotechnology firms expanded tetravalent vaccine development initiatives by 27% to improve cross-serotype immune response consistency. Clinical studies reported neutralizing antibody response rates above 70% for several next-generation vaccine candidates. Temperature-stable formulations improved vaccine storage efficiency by 15%, supporting immunization programs in remote tropical areas with limited refrigeration infrastructure.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, Takeda Pharmaceutical expanded Tak-003 regulatory approvals into additional endemic countries, increasing global vaccine access coverage by 18%.
• In 2024, Sanofi strengthened dengue vaccine production capacity by 21% to support rising public immunization demand across Latin America and Southeast Asia.
• During 2024, multiple biotechnology firms initiated over 6 advanced clinical trials for next-generation tetravalent dengue vaccines targeting improved serotype protection.
• In 2025, government procurement agreements for dengue vaccines increased by 31% across Asia-Pacific due to rising seasonal outbreaks and pediatric hospitalization rates.
• In 2025, research institutions expanded mRNA dengue vaccine development collaborations by 26%, accelerating experimental vaccine platform evaluations and immunogenicity studies.

DENGUE VACCINES MARKET REPORT COVERAGE

The Dengue Vaccines Market report provides detailed analysis of vaccine technologies, disease prevalence, immunization programs, and regional healthcare initiatives. The report evaluates market performance across North America, Europe, Asia-Pacific, and Middle East & Africa using verified epidemiological and vaccination data. More than 129 dengue-endemic countries are analyzed within the report framework, while over 5.2 million reported dengue cases are considered for market assessment.

The report includes segmentation analysis by vaccine type and application, covering CYD-TDV, Tak-003, hospitals, government institutes, and NGOs. Market share evaluation highlights that Asia-Pacific accounts for 52% of global vaccine demand, while hospitals contribute nearly 49% of vaccine administration activities. Pediatric populations representing 61% of vaccinated individuals are also examined in detail.